MktsMarkets
Annovis Bio, Inc.
NYSE: ANVSKey statistics
ANVS News
Stories mentioning ANVS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | ||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Operating Expenses | ||||||||
| Research & Development | 16,720 | 8,751 | 6,291 | 5,162 | 5,012 | 5,005 | 2,690 | 5,785 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 18,012 | 9,706 | 7,435 | 6,271 | 6,283 | 6,734 | 4,388 | 7,763 |
| Operating Income (Loss) | (18,012) | (9,706) | (7,435) | (6,271) | (6,283) | (6,734) | (4,388) | (7,763) |
| Interest Income | 138.00 | 168.00 | 152.00 | 191.00 | 188.00 | 127.00 | 135.00 | 26.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (12,638) | (5,020) | ||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income (Loss) | (17,606) | (9,834) | (7,263) | (6,220) | (5,537) | (5,865) | (12,638) | (5,020) |
| Earnings Per Share (Basic) | (0.63) | (0.48) | (0.37) | (0.32) | (0.32) | (0.48) | (0.97) | (0.44) |
| Earnings Per Share (Diluted) | (0.63) | (0.48) | (0.37) | (0.32) | (0.32) | (0.48) | (0.97) | (0.44) |
| Weighted Average Shares Outstanding (Basic) | 27,848 | 20,552 | 19,685 | 19,486 | 17,431 | 12,182 | 12,976 | 11,308 |
| Weighted Average Shares Outstanding (Diluted) | 27,848 | 20,552 | 19,685 | 19,486 | 17,431 | 12,235 | 12,976 | 11,308 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ANVS
Annovis Bio, Inc. (NYSE: ANVS) is a stock listed on the New York Stock Exchange under the ticker symbol ANVS. It last traded at $1.08 (Nov 2, 2026, 9:30 AM ET), down 4.4% on the day. That gives Annovis Bio a market capitalisation of $49.1M.
Over the past 52 weeks ANVS has traded between $0.9300 and $5.50.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $17.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$17.6M |
| Dec 31, 2025 | — | -$9.8M |
| Sep 30, 2025 | — | -$7.3M |
| Jun 30, 2025 | — | -$6.2M |
From Annovis Bio’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…